News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Repros Therapeutics Inc. Provides Additional Information on Proellex(R) Clinical Program
July 7, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics (NasdaqGM:RPRX) provides a further update on the clinical development of Proellex 25 and 12.5 mg doses.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
MORE ON THIS TOPIC
Lung cancer
Cullinan, Taiho’s NSCLC Hopeful Shows ‘Strong Activity,’ Clearing Road to FDA
September 10, 2025
·
2 min read
·
Tristan Manalac
Podcast
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
September 10, 2025
·
1 min read
·
Jef Akst
Lung cancer
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC
September 9, 2025
·
2 min read
·
Tristan Manalac
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
September 9, 2025
·
2 min read
·
Tristan Manalac
